Sections
Shows
Events
Dr Reddy's PAT surges 45% at Rs 485 cr in Q3; revenues from North America decline 8% to Rs 1,480 cr
Decks cleared for resuming launch of Dr Reddy’s generic Suboxone after US court rejects rival firm’s patent breach case